Skip to main content

Table 5 Antifungal susceptibilities of 33 Candida parapsilosis isolates

From: Incidence, susceptibility and outcomes of candidemia in adults living in Calgary, Alberta, Canada (2010–2018)

Methodology

Antifungal

No.

MIC50

MIC90

Susceptible

Resistant

   

(µg/mL)

(µg/mL)

(%)

(%)

95% CI

CLSI

Caspofungin

33

0.5

0.5

100.0

0.0

0.0–10.6

Breakpoints

Micafungin

29

1

2

100.0

0.0

0.0–11.9

 

Fluconazole

33

0.5

1

100.0

0.0

0.0–10.6

 

Voriconazole

33

0.008

0.015

100.0

0.0

0.0–10.6

  

No.

MIC50

MIC90

WT1

NWT2

95% CI

   

(µg/mL)

(µg/mL)

(%)

(%)

 

CLSI

Amphotericin B

33

0.5

0.5

100.0

0.0

0.0–10.6

ECV3

Posaconazole

15

0.03

0.06

100.0

0.0

0.0–21.8

  1. 1Wild type
  2. 2Non-wild type
  3. 3Epidemiological cut-off value